IRINOTECAN VIATRIS 20 mg/ml
Sponsors
Institut De Cancerologie De L Ouest, Institut Regional Du Cancer De Montpellier, Intergroupe Francophone De Cancerologie Thoracique, Association Gercor, Associazione Italiana Per Lo Studio Del Pancreas
Conditions
Advanced pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs)Patients with newly diagnosed advanced peritoneal metastasis from colorectal cancerlocal advenced pancreatic adenocarcinomalocally advanced or metastatic Pancreatic ductal adenocarcinomapancreatic ductal adenocarcinoma
Phase 2
PHASE II study evaluating the benefit of Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
RecruitingCTIS2024-515344-23-00
Start: 2021-06-17Target: 103Updated: 2025-03-24
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a multicentre phase II randomized trial (PIPOX02)
RecruitingCTIS2024-514560-10-00
Start: 2025-06-12Target: 114Updated: 2024-10-11
A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma.
Not yet recruitingCTIS2024-518139-12-00
Target: 106Updated: 2024-11-14
Phase 3
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
Not yet recruitingCTIS2024-519031-42-00
Target: 261Updated: 2024-11-18
GCO-003 TARLANEC A randomized phase III trial study comparing tarlatamab with standard of care chemotherapy in patients with pre-treated advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas
Not yet recruitingCTIS2024-515948-23-00
Target: 129Updated: 2025-09-02